Anthony Elias
Concepts (665)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 111 | 2026 | 2411 | 5.850 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 97 | 2026 | 1996 | 3.800 |
Why?
| | Sarcoma | 33 | 2025 | 209 | 3.600 |
Why?
| | Receptors, Estrogen | 22 | 2021 | 405 | 2.190 |
Why?
| | Triple Negative Breast Neoplasms | 14 | 2024 | 219 | 2.130 |
Why?
| | Hematopoietic Stem Cell Transplantation | 36 | 2011 | 700 | 1.820 |
Why?
| | Carcinoma, Small Cell | 19 | 2003 | 172 | 1.620 |
Why?
| | Soft Tissue Neoplasms | 14 | 2022 | 133 | 1.480 |
Why?
| | Neoadjuvant Therapy | 19 | 2026 | 474 | 1.450 |
Why?
| | Carcinoma, Ductal, Breast | 7 | 2018 | 91 | 1.400 |
Why?
| | Antineoplastic Agents | 31 | 2023 | 2218 | 1.160 |
Why?
| | Neoplasm Staging | 38 | 2026 | 1486 | 1.120 |
Why?
| | Neoplasm Recurrence, Local | 20 | 2022 | 1156 | 1.070 |
Why?
| | Receptors, Progesterone | 13 | 2020 | 241 | 1.030 |
Why?
| | Combined Modality Therapy | 52 | 2024 | 1269 | 0.950 |
Why?
| | Lung Neoplasms | 38 | 2003 | 2674 | 0.950 |
Why?
| | Doxorubicin | 24 | 2025 | 414 | 0.920 |
Why?
| | Biomarkers, Tumor | 17 | 2022 | 1334 | 0.910 |
Why?
| | Antibodies, Monoclonal, Humanized | 11 | 2026 | 992 | 0.910 |
Why?
| | Paclitaxel | 14 | 2024 | 258 | 0.860 |
Why?
| | Bone Marrow Transplantation | 27 | 1998 | 298 | 0.860 |
Why?
| | CTLA-4 Antigen | 1 | 2025 | 105 | 0.850 |
Why?
| | Mastectomy | 9 | 2018 | 188 | 0.820 |
Why?
| | Bone Neoplasms | 7 | 2025 | 271 | 0.800 |
Why?
| | Antineoplastic Agents, Alkylating | 5 | 2018 | 76 | 0.700 |
Why?
| | Female | 171 | 2026 | 79080 | 0.700 |
Why?
| | Receptors, Androgen | 7 | 2018 | 149 | 0.690 |
Why?
| | Humans | 229 | 2026 | 145625 | 0.670 |
Why?
| | Disease-Free Survival | 24 | 2023 | 777 | 0.660 |
Why?
| | Middle Aged | 113 | 2026 | 36359 | 0.630 |
Why?
| | Maytansine | 3 | 2021 | 18 | 0.620 |
Why?
| | Antineoplastic Agents, Hormonal | 10 | 2018 | 196 | 0.620 |
Why?
| | Liposarcoma | 4 | 2023 | 31 | 0.620 |
Why?
| | Neoplasm Metastasis | 23 | 2024 | 693 | 0.560 |
Why?
| | Adult | 115 | 2026 | 40821 | 0.560 |
Why?
| | Chemotherapy, Adjuvant | 23 | 2023 | 429 | 0.550 |
Why?
| | Dioxoles | 2 | 2015 | 9 | 0.530 |
Why?
| | Tetrahydroisoquinolines | 2 | 2015 | 8 | 0.530 |
Why?
| | Cyclophosphamide | 31 | 2024 | 275 | 0.530 |
Why?
| | Androgen Receptor Antagonists | 6 | 2021 | 35 | 0.490 |
Why?
| | Ifosfamide | 19 | 1998 | 39 | 0.490 |
Why?
| | Phenylthiohydantoin | 5 | 2017 | 44 | 0.480 |
Why?
| | Dasatinib | 1 | 2016 | 58 | 0.480 |
Why?
| | Aged | 65 | 2025 | 26251 | 0.480 |
Why?
| | Trastuzumab | 10 | 2024 | 119 | 0.460 |
Why?
| | Neoplasms, Hormone-Dependent | 3 | 2012 | 33 | 0.460 |
Why?
| | Treatment Outcome | 43 | 2024 | 11744 | 0.430 |
Why?
| | Drug Administration Schedule | 24 | 2018 | 782 | 0.430 |
Why?
| | Carboplatin | 21 | 2016 | 168 | 0.420 |
Why?
| | Estrogen Receptor alpha | 5 | 2021 | 154 | 0.420 |
Why?
| | Granulocyte Colony-Stimulating Factor | 11 | 2002 | 90 | 0.410 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 17 | 2001 | 1194 | 0.390 |
Why?
| | Clinical Trials as Topic | 19 | 2018 | 1062 | 0.390 |
Why?
| | Estrogens | 6 | 2018 | 364 | 0.380 |
Why?
| | Medical Oncology | 6 | 2026 | 344 | 0.370 |
Why?
| | Dacarbazine | 9 | 2018 | 98 | 0.370 |
Why?
| | Tamoxifen | 9 | 2018 | 193 | 0.350 |
Why?
| | Survival Rate | 19 | 2021 | 2078 | 0.340 |
Why?
| | Survival Analysis | 23 | 2010 | 1372 | 0.330 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 973 | 0.330 |
Why?
| | Neoplasms | 20 | 2009 | 2944 | 0.330 |
Why?
| | Prognosis | 22 | 2021 | 4331 | 0.330 |
Why?
| | Venous Thromboembolism | 3 | 2020 | 330 | 0.320 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2025 | 268 | 0.320 |
Why?
| | Pyrimidines | 3 | 2020 | 530 | 0.320 |
Why?
| | Neoplasms, Second Primary | 3 | 2022 | 103 | 0.320 |
Why?
| | Dose-Response Relationship, Drug | 17 | 2017 | 2018 | 0.320 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 3 | 2022 | 61 | 0.320 |
Why?
| | Antibodies, Monoclonal | 9 | 2024 | 1511 | 0.310 |
Why?
| | Taxoids | 7 | 2023 | 115 | 0.310 |
Why?
| | Remission Induction | 16 | 2002 | 308 | 0.300 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 8 | 1999 | 158 | 0.300 |
Why?
| | Breast Neoplasms, Male | 3 | 2018 | 29 | 0.300 |
Why?
| | Drug Resistance, Neoplasm | 7 | 2017 | 889 | 0.280 |
Why?
| | Gene Expression Regulation, Neoplastic | 11 | 2018 | 1429 | 0.280 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2020 | 81 | 0.280 |
Why?
| | Mesna | 12 | 1998 | 15 | 0.270 |
Why?
| | Sarcoma, Ewing | 3 | 2022 | 103 | 0.260 |
Why?
| | Leiomyosarcoma | 2 | 2018 | 30 | 0.250 |
Why?
| | Cisplatin | 14 | 2000 | 346 | 0.240 |
Why?
| | Sternum | 1 | 2006 | 26 | 0.240 |
Why?
| | Immunoconjugates | 3 | 2024 | 138 | 0.240 |
Why?
| | Immunohistochemistry | 5 | 2016 | 1709 | 0.240 |
Why?
| | Tumor Microenvironment | 4 | 2024 | 745 | 0.230 |
Why?
| | Mastectomy, Segmental | 2 | 2009 | 107 | 0.230 |
Why?
| | Chondrosarcoma | 1 | 2025 | 17 | 0.220 |
Why?
| | Carcinoma, Ductal | 1 | 2005 | 10 | 0.220 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 2 | 2002 | 35 | 0.220 |
Why?
| | Melphalan | 10 | 2002 | 43 | 0.220 |
Why?
| | Pyridines | 2 | 2025 | 606 | 0.220 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2025 | 71 | 0.220 |
Why?
| | Transplantation, Autologous | 19 | 2002 | 303 | 0.210 |
Why?
| | Cell Adhesion Molecules | 2 | 2021 | 180 | 0.210 |
Why?
| | Carcinoma | 2 | 2008 | 225 | 0.210 |
Why?
| | Lymph Nodes | 1 | 2007 | 511 | 0.210 |
Why?
| | Male | 66 | 2025 | 73014 | 0.210 |
Why?
| | Protein Kinase Inhibitors | 4 | 2019 | 982 | 0.210 |
Why?
| | Risk Reduction Behavior | 2 | 2016 | 219 | 0.210 |
Why?
| | Drug Evaluation | 19 | 1998 | 78 | 0.200 |
Why?
| | Glycine | 1 | 2025 | 184 | 0.200 |
Why?
| | Adjuvants, Immunologic | 3 | 2022 | 243 | 0.200 |
Why?
| | Ribonuclease III | 2 | 2016 | 44 | 0.200 |
Why?
| | Deoxycytidine | 4 | 2020 | 219 | 0.200 |
Why?
| | Ovarian Neoplasms | 3 | 2022 | 598 | 0.190 |
Why?
| | Survivors | 3 | 2016 | 521 | 0.190 |
Why?
| | Thiotepa | 13 | 2002 | 21 | 0.190 |
Why?
| | Alkylating Agents | 3 | 2000 | 23 | 0.190 |
Why?
| | Hodgkin Disease | 4 | 2016 | 173 | 0.190 |
Why?
| | DEAD-box RNA Helicases | 2 | 2016 | 89 | 0.190 |
Why?
| | Triazoles | 2 | 2022 | 190 | 0.190 |
Why?
| | Behavior Therapy | 2 | 2016 | 290 | 0.180 |
Why?
| | Weight Loss | 4 | 2016 | 857 | 0.180 |
Why?
| | Gene Expression Profiling | 6 | 2017 | 1790 | 0.180 |
Why?
| | Disease Management | 5 | 2020 | 649 | 0.180 |
Why?
| | Aged, 80 and over | 14 | 2021 | 8351 | 0.180 |
Why?
| | Employment | 1 | 2024 | 180 | 0.180 |
Why?
| | Mutation | 4 | 2025 | 4082 | 0.180 |
Why?
| | Obesity | 4 | 2018 | 3123 | 0.180 |
Why?
| | Hydrazines | 1 | 2022 | 37 | 0.180 |
Why?
| | Overweight | 3 | 2016 | 613 | 0.180 |
Why?
| | Salvage Therapy | 6 | 2010 | 163 | 0.180 |
Why?
| | Carcinoma in Situ | 2 | 2012 | 45 | 0.170 |
Why?
| | Circulating Tumor DNA | 1 | 2022 | 50 | 0.170 |
Why?
| | Etoposide | 10 | 2001 | 169 | 0.170 |
Why?
| | Tumor Cells, Cultured | 9 | 2020 | 878 | 0.170 |
Why?
| | Hematologic Diseases | 6 | 2008 | 66 | 0.170 |
Why?
| | Sarcoma, Synovial | 1 | 2021 | 20 | 0.170 |
Why?
| | Liposarcoma, Myxoid | 1 | 2021 | 10 | 0.170 |
Why?
| | Recombinant Fusion Proteins | 1 | 2024 | 662 | 0.160 |
Why?
| | Emergency Medicine | 1 | 2024 | 278 | 0.160 |
Why?
| | Referral and Consultation | 1 | 2007 | 878 | 0.160 |
Why?
| | Endpoint Determination | 1 | 2021 | 84 | 0.160 |
Why?
| | Aromatase Inhibitors | 4 | 2021 | 81 | 0.160 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2017 | 117 | 0.160 |
Why?
| | Cell Separation | 3 | 2017 | 300 | 0.160 |
Why?
| | Indazoles | 1 | 2020 | 86 | 0.160 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 48 | 0.160 |
Why?
| | Leukocytes, Mononuclear | 3 | 2020 | 585 | 0.160 |
Why?
| | Antigens, Neoplasm | 4 | 2021 | 271 | 0.150 |
Why?
| | Time Factors | 12 | 2020 | 7079 | 0.150 |
Why?
| | Hematopoietic Stem Cells | 5 | 1996 | 432 | 0.150 |
Why?
| | Diphosphonates | 1 | 2020 | 67 | 0.150 |
Why?
| | Diet | 3 | 2018 | 1271 | 0.150 |
Why?
| | Pyrroles | 2 | 2013 | 221 | 0.150 |
Why?
| | Bone Marrow | 8 | 2000 | 308 | 0.150 |
Why?
| | Nuclear Medicine | 1 | 2019 | 9 | 0.150 |
Why?
| | Hematology | 1 | 2019 | 21 | 0.140 |
Why?
| | Bridged-Ring Compounds | 4 | 2023 | 31 | 0.140 |
Why?
| | Cell Line, Tumor | 9 | 2017 | 3538 | 0.140 |
Why?
| | MCF-7 Cells | 5 | 2017 | 133 | 0.140 |
Why?
| | Proportional Hazards Models | 6 | 2020 | 1318 | 0.140 |
Why?
| | CA-125 Antigen | 2 | 2013 | 13 | 0.140 |
Why?
| | Fluorouracil | 7 | 2013 | 231 | 0.140 |
Why?
| | Pyrazoles | 2 | 2022 | 516 | 0.140 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2020 | 218 | 0.140 |
Why?
| | Pulmonary Medicine | 1 | 2019 | 78 | 0.140 |
Why?
| | Thromboembolism | 1 | 2019 | 129 | 0.140 |
Why?
| | Bayes Theorem | 4 | 2024 | 424 | 0.130 |
Why?
| | Benzamides | 5 | 2017 | 226 | 0.130 |
Why?
| | Research Design | 3 | 2021 | 1139 | 0.130 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 59 | 0.130 |
Why?
| | Nitriles | 5 | 2017 | 211 | 0.130 |
Why?
| | Tissue Inhibitor of Metalloproteinase-3 | 1 | 2017 | 9 | 0.130 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2018 | 52 | 0.130 |
Why?
| | Cell Cycle | 1 | 2021 | 595 | 0.130 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2018 | 49 | 0.130 |
Why?
| | Infusions, Intravenous | 10 | 2020 | 429 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 6 | 2018 | 959 | 0.130 |
Why?
| | Schwann Cells | 1 | 2017 | 33 | 0.130 |
Why?
| | Tetrahydronaphthalenes | 1 | 2017 | 34 | 0.130 |
Why?
| | Vaccines | 1 | 2022 | 389 | 0.130 |
Why?
| | Sciatic Nerve | 1 | 2017 | 63 | 0.130 |
Why?
| | Microbubbles | 1 | 2017 | 51 | 0.130 |
Why?
| | Valine | 1 | 2017 | 84 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.120 |
Why?
| | Societies, Medical | 2 | 2019 | 901 | 0.120 |
Why?
| | Venous Thrombosis | 1 | 2019 | 195 | 0.120 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2017 | 80 | 0.120 |
Why?
| | Lymph Node Excision | 3 | 2015 | 173 | 0.120 |
Why?
| | Camptothecin | 3 | 2024 | 139 | 0.120 |
Why?
| | Indoles | 2 | 2013 | 509 | 0.120 |
Why?
| | Axilla | 3 | 2017 | 51 | 0.120 |
Why?
| | Androgen Antagonists | 2 | 2015 | 91 | 0.120 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 23 | 0.120 |
Why?
| | Sulfonamides | 1 | 2020 | 592 | 0.120 |
Why?
| | Gonadal Steroid Hormones | 1 | 2018 | 143 | 0.120 |
Why?
| | Immunotherapy | 2 | 2018 | 669 | 0.120 |
Why?
| | Hematopoietic Cell Growth Factors | 2 | 1995 | 5 | 0.120 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 1995 | 76 | 0.120 |
Why?
| | Ultrasonography, Mammary | 1 | 2016 | 17 | 0.120 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2016 | 100 | 0.120 |
Why?
| | Lymphatic Metastasis | 3 | 2017 | 335 | 0.120 |
Why?
| | Antibody Specificity | 1 | 2016 | 181 | 0.120 |
Why?
| | Anesthesiology | 1 | 2019 | 178 | 0.120 |
Why?
| | Internship and Residency | 2 | 2024 | 1269 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2023 | 530 | 0.120 |
Why?
| | Thiazoles | 1 | 2016 | 139 | 0.120 |
Why?
| | Neoplasm Invasiveness | 3 | 2016 | 503 | 0.120 |
Why?
| | Follow-Up Studies | 6 | 2025 | 5397 | 0.110 |
Why?
| | Myelin Sheath | 1 | 2017 | 166 | 0.110 |
Why?
| | Maximum Tolerated Dose | 1 | 2016 | 216 | 0.110 |
Why?
| | Neoplastic Stem Cells | 2 | 2017 | 402 | 0.110 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2016 | 140 | 0.110 |
Why?
| | Benzimidazoles | 1 | 2016 | 189 | 0.110 |
Why?
| | Ambulatory Care | 1 | 2020 | 627 | 0.110 |
Why?
| | Quinolines | 1 | 2016 | 191 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.110 |
Why?
| | Drug Therapy, Combination | 4 | 2014 | 1034 | 0.110 |
Why?
| | Recurrence | 5 | 2020 | 1125 | 0.110 |
Why?
| | Mammography | 1 | 2016 | 172 | 0.100 |
Why?
| | Animals | 17 | 2021 | 38030 | 0.100 |
Why?
| | Radiotherapy, Adjuvant | 5 | 2016 | 222 | 0.100 |
Why?
| | Disease Progression | 7 | 2018 | 2857 | 0.100 |
Why?
| | Homeodomain Proteins | 2 | 2018 | 525 | 0.100 |
Why?
| | Hepatic Veno-Occlusive Disease | 3 | 2002 | 12 | 0.100 |
Why?
| | Brain Edema | 1 | 2014 | 63 | 0.100 |
Why?
| | Administration, Oral | 4 | 2020 | 867 | 0.100 |
Why?
| | Antibodies | 1 | 2016 | 395 | 0.100 |
Why?
| | Radiotherapy Dosage | 3 | 1999 | 289 | 0.100 |
Why?
| | Keratins | 2 | 2017 | 57 | 0.100 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2017 | 454 | 0.100 |
Why?
| | Young Adult | 10 | 2025 | 14240 | 0.100 |
Why?
| | Testicular Neoplasms | 1 | 1995 | 108 | 0.100 |
Why?
| | Vascular Neoplasms | 1 | 2013 | 19 | 0.100 |
Why?
| | Clinical Trials, Phase I as Topic | 3 | 2024 | 49 | 0.100 |
Why?
| | Comorbidity | 5 | 2017 | 1652 | 0.100 |
Why?
| | Radiotherapy | 3 | 2015 | 209 | 0.100 |
Why?
| | Apoptosis | 6 | 2023 | 2436 | 0.100 |
Why?
| | Exercise | 2 | 2015 | 2206 | 0.100 |
Why?
| | Epigenesis, Genetic | 2 | 2018 | 705 | 0.100 |
Why?
| | Cellular Reprogramming | 1 | 2014 | 98 | 0.100 |
Why?
| | Mercaptoethanol | 2 | 1990 | 8 | 0.100 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2022 | 137 | 0.100 |
Why?
| | Mice | 12 | 2021 | 18266 | 0.090 |
Why?
| | Adenocarcinoma | 6 | 2015 | 927 | 0.090 |
Why?
| | Cell Proliferation | 6 | 2017 | 2497 | 0.090 |
Why?
| | Gallium Radioisotopes | 1 | 1992 | 16 | 0.090 |
Why?
| | Patient Selection | 4 | 2016 | 720 | 0.090 |
Why?
| | Bone Marrow Cells | 4 | 2000 | 326 | 0.090 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2022 | 429 | 0.090 |
Why?
| | Carmustine | 10 | 2001 | 52 | 0.090 |
Why?
| | Chromatin | 1 | 2016 | 557 | 0.090 |
Why?
| | Adolescent | 23 | 2025 | 22451 | 0.090 |
Why?
| | Anthracyclines | 3 | 2023 | 49 | 0.090 |
Why?
| | Methotrexate | 4 | 2002 | 234 | 0.090 |
Why?
| | Lymphoma, Non-Hodgkin | 3 | 2001 | 124 | 0.090 |
Why?
| | Brain Neoplasms | 5 | 2014 | 1324 | 0.080 |
Why?
| | Neoplasm, Residual | 2 | 2022 | 143 | 0.080 |
Why?
| | Weight Reduction Programs | 1 | 2012 | 140 | 0.080 |
Why?
| | Retrospective Studies | 12 | 2023 | 17291 | 0.080 |
Why?
| | RNA, Catalytic | 1 | 2012 | 191 | 0.080 |
Why?
| | Polydeoxyribonucleotides | 2 | 2002 | 14 | 0.080 |
Why?
| | Age Factors | 5 | 2019 | 3321 | 0.080 |
Why?
| | Risk Assessment | 3 | 2020 | 3678 | 0.080 |
Why?
| | Multivariate Analysis | 4 | 2013 | 1531 | 0.080 |
Why?
| | Neutropenia | 5 | 2013 | 153 | 0.080 |
Why?
| | Neoplasm Grading | 3 | 2017 | 313 | 0.080 |
Why?
| | Leukapheresis | 4 | 2001 | 27 | 0.080 |
Why?
| | Aorta | 1 | 2013 | 440 | 0.080 |
Why?
| | Carcinoma, Lobular | 1 | 2011 | 59 | 0.080 |
Why?
| | Radiosurgery | 1 | 2014 | 398 | 0.080 |
Why?
| | Keratin-5 | 1 | 2010 | 43 | 0.080 |
Why?
| | Biopsy | 3 | 2018 | 1073 | 0.080 |
Why?
| | Angiogenesis Inhibitors | 1 | 2012 | 238 | 0.080 |
Why?
| | Liver Neoplasms | 3 | 2015 | 774 | 0.080 |
Why?
| | Peptide Mapping | 1 | 2010 | 61 | 0.080 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 109 | 0.080 |
Why?
| | Molecular Targeted Therapy | 3 | 2018 | 446 | 0.080 |
Why?
| | Piperazines | 2 | 2023 | 367 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1370 | 0.070 |
Why?
| | Databases, Protein | 1 | 2010 | 88 | 0.070 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 143 | 0.070 |
Why?
| | Urinary Tract | 1 | 1990 | 47 | 0.070 |
Why?
| | Benzenesulfonates | 1 | 2009 | 23 | 0.070 |
Why?
| | CD146 Antigen | 2 | 2021 | 38 | 0.070 |
Why?
| | Postmenopause | 2 | 2017 | 394 | 0.070 |
Why?
| | BRCA2 Protein | 1 | 2009 | 68 | 0.070 |
Why?
| | Health Facilities | 1 | 2009 | 85 | 0.070 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2009 | 64 | 0.070 |
Why?
| | Observer Variation | 1 | 2010 | 355 | 0.070 |
Why?
| | Thrombophilia | 1 | 2009 | 89 | 0.070 |
Why?
| | Patient Care | 1 | 2009 | 120 | 0.070 |
Why?
| | Risk Factors | 8 | 2020 | 10840 | 0.070 |
Why?
| | Mice, Nude | 3 | 2017 | 665 | 0.070 |
Why?
| | Perimenopause | 1 | 2008 | 69 | 0.070 |
Why?
| | United States | 9 | 2023 | 16041 | 0.070 |
Why?
| | Fibrinolytic Agents | 2 | 2002 | 302 | 0.060 |
Why?
| | In Situ Hybridization | 2 | 2010 | 317 | 0.060 |
Why?
| | Bone Marrow Diseases | 4 | 2000 | 20 | 0.060 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2008 | 333 | 0.060 |
Why?
| | Blotting, Western | 1 | 2010 | 1176 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2017 | 928 | 0.060 |
Why?
| | Fatigue | 3 | 2018 | 362 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2000 | 1754 | 0.060 |
Why?
| | Sputum | 1 | 1988 | 302 | 0.060 |
Why?
| | Pneumonectomy | 3 | 1997 | 167 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2016 | 3396 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2019 | 438 | 0.060 |
Why?
| | Quality of Life | 2 | 2015 | 3187 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2007 | 443 | 0.060 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 364 | 0.050 |
Why?
| | Life Tables | 2 | 2002 | 21 | 0.050 |
Why?
| | Anilides | 2 | 2016 | 82 | 0.050 |
Why?
| | New Jersey | 1 | 2024 | 17 | 0.050 |
Why?
| | Colony-Stimulating Factors | 3 | 1988 | 37 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 342 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 820 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2016 | 2097 | 0.050 |
Why?
| | Receptor, TIE-2 | 1 | 2024 | 11 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2012 | 751 | 0.050 |
Why?
| | Granulocytes | 4 | 1995 | 82 | 0.050 |
Why?
| | New York | 1 | 2024 | 127 | 0.050 |
Why?
| | MicroRNAs | 1 | 2010 | 695 | 0.050 |
Why?
| | Growth Substances | 3 | 1988 | 136 | 0.050 |
Why?
| | Ricin | 2 | 1997 | 8 | 0.050 |
Why?
| | Genes, Neoplasm | 1 | 2004 | 26 | 0.050 |
Why?
| | Forecasting | 3 | 2000 | 386 | 0.050 |
Why?
| | Thrombocytopenia | 3 | 2013 | 205 | 0.050 |
Why?
| | Up-Regulation | 2 | 2017 | 840 | 0.050 |
Why?
| | Patient Care Planning | 1 | 2005 | 170 | 0.050 |
Why?
| | Anticoagulants | 2 | 2019 | 743 | 0.050 |
Why?
| | Activating Transcription Factor 4 | 1 | 2023 | 22 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2023 | 42 | 0.050 |
Why?
| | Signal Transduction | 5 | 2018 | 5234 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2016 | 3917 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2023 | 66 | 0.050 |
Why?
| | G(M2) Ganglioside | 1 | 2022 | 1 | 0.050 |
Why?
| | Injection Site Reaction | 1 | 2022 | 4 | 0.050 |
Why?
| | Cyclin E | 1 | 2022 | 23 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2000 | 116 | 0.050 |
Why?
| | Mammaplasty | 2 | 2016 | 148 | 0.050 |
Why?
| | Proteomics | 1 | 2010 | 1202 | 0.050 |
Why?
| | Treatment Failure | 2 | 2001 | 358 | 0.050 |
Why?
| | Luminescent Measurements | 1 | 2003 | 75 | 0.050 |
Why?
| | France | 2 | 2019 | 40 | 0.050 |
Why?
| | Oncogene Proteins | 1 | 2022 | 61 | 0.050 |
Why?
| | Ribose | 1 | 2022 | 21 | 0.050 |
Why?
| | Blood Transfusion, Autologous | 2 | 1993 | 18 | 0.050 |
Why?
| | Carbolines | 1 | 2022 | 35 | 0.050 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2022 | 24 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2023 | 155 | 0.050 |
Why?
| | Transcriptome | 2 | 2023 | 1066 | 0.040 |
Why?
| | Adenosine Diphosphate | 1 | 2022 | 75 | 0.040 |
Why?
| | Career Choice | 1 | 2024 | 235 | 0.040 |
Why?
| | Imidazoles | 1 | 2023 | 244 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2022 | 124 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 109 | 0.040 |
Why?
| | Actuarial Analysis | 2 | 1993 | 15 | 0.040 |
Why?
| | Oncogenes | 1 | 2022 | 113 | 0.040 |
Why?
| | Cell Division | 2 | 2001 | 735 | 0.040 |
Why?
| | Gene Expression | 2 | 2020 | 1461 | 0.040 |
Why?
| | Colony-Forming Units Assay | 4 | 1996 | 95 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2015 | 2766 | 0.040 |
Why?
| | Carcinoembryonic Antigen | 1 | 2001 | 40 | 0.040 |
Why?
| | Phthalazines | 1 | 2021 | 63 | 0.040 |
Why?
| | Transplantation Immunology | 1 | 2000 | 28 | 0.040 |
Why?
| | Clodronic Acid | 1 | 2020 | 19 | 0.040 |
Why?
| | Progesterone | 1 | 2002 | 214 | 0.040 |
Why?
| | Prospective Studies | 5 | 2022 | 8087 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 353 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 676 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 384 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2012 | 3005 | 0.040 |
Why?
| | Estradiol | 2 | 2016 | 517 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2024 | 564 | 0.040 |
Why?
| | Topoisomerase I Inhibitors | 1 | 1999 | 20 | 0.040 |
Why?
| | Thoracotomy | 2 | 1997 | 87 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2003 | 1030 | 0.040 |
Why?
| | Leucovorin | 2 | 1997 | 98 | 0.040 |
Why?
| | Hematopoietic Stem Cell Mobilization | 1 | 1999 | 28 | 0.040 |
Why?
| | Bone Density Conservation Agents | 1 | 2020 | 82 | 0.040 |
Why?
| | Mechlorethamine | 1 | 2000 | 52 | 0.040 |
Why?
| | Dendritic Cells | 2 | 2000 | 507 | 0.040 |
Why?
| | Neoplasms, Experimental | 1 | 2000 | 163 | 0.040 |
Why?
| | Drug Resistance | 1 | 1999 | 145 | 0.040 |
Why?
| | Receptors, Steroid | 1 | 2019 | 41 | 0.040 |
Why?
| | Cluster Analysis | 2 | 2012 | 494 | 0.040 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 44 | 0.040 |
Why?
| | Myelodysplastic Syndromes | 1 | 2001 | 170 | 0.030 |
Why?
| | Etanidazole | 1 | 1998 | 1 | 0.030 |
Why?
| | Child | 8 | 2022 | 22638 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2022 | 629 | 0.030 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1998 | 29 | 0.030 |
Why?
| | Leukemia | 1 | 2001 | 246 | 0.030 |
Why?
| | Expectorants | 1 | 1998 | 22 | 0.030 |
Why?
| | Aurora Kinase A | 1 | 2018 | 57 | 0.030 |
Why?
| | Loss of Function Mutation | 1 | 2018 | 47 | 0.030 |
Why?
| | Nervous System | 2 | 1997 | 68 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2020 | 339 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2020 | 612 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 1999 | 423 | 0.030 |
Why?
| | Mediastinum | 1 | 1998 | 23 | 0.030 |
Why?
| | Retreatment | 1 | 2018 | 79 | 0.030 |
Why?
| | Nausea | 1 | 2018 | 111 | 0.030 |
Why?
| | Epithelial Cell Adhesion Molecule | 1 | 2017 | 10 | 0.030 |
Why?
| | Myelin Basic Protein | 1 | 2017 | 44 | 0.030 |
Why?
| | ADAM17 Protein | 1 | 2017 | 42 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2018 | 172 | 0.030 |
Why?
| | Bromodeoxyuridine | 1 | 2017 | 74 | 0.030 |
Why?
| | Extremities | 2 | 1989 | 142 | 0.030 |
Why?
| | Breast | 1 | 2018 | 154 | 0.030 |
Why?
| | SEER Program | 1 | 2018 | 233 | 0.030 |
Why?
| | Watchful Waiting | 1 | 2018 | 90 | 0.030 |
Why?
| | Diarrhea | 1 | 2018 | 190 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 1998 | 247 | 0.030 |
Why?
| | Ganglia, Spinal | 1 | 2017 | 88 | 0.030 |
Why?
| | Thorax | 1 | 1997 | 51 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2022 | 2064 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2017 | 244 | 0.030 |
Why?
| | Random Allocation | 2 | 1988 | 365 | 0.030 |
Why?
| | Phosphoramide Mustards | 1 | 2016 | 3 | 0.030 |
Why?
| | Medicare | 1 | 2023 | 907 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 143 | 0.030 |
Why?
| | Immunotoxins | 1 | 1997 | 51 | 0.030 |
Why?
| | Everolimus | 1 | 2017 | 112 | 0.030 |
Why?
| | Cyclohexanes | 1 | 2016 | 21 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2017 | 4112 | 0.030 |
Why?
| | Cell Survival | 1 | 2000 | 1102 | 0.030 |
Why?
| | Cohort Studies | 4 | 2001 | 6045 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2017 | 93 | 0.030 |
Why?
| | Placebos | 1 | 2016 | 190 | 0.030 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2017 | 180 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 334 | 0.030 |
Why?
| | Ascorbic Acid | 1 | 2017 | 183 | 0.030 |
Why?
| | Injections, Intravenous | 2 | 1993 | 197 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2018 | 226 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 200 | 0.030 |
Why?
| | Blood Specimen Collection | 1 | 1995 | 37 | 0.030 |
Why?
| | Fertility Preservation | 1 | 2016 | 57 | 0.030 |
Why?
| | Organoplatinum Compounds | 3 | 1990 | 65 | 0.030 |
Why?
| | Antidotes | 1 | 1997 | 145 | 0.030 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 1998 | 195 | 0.030 |
Why?
| | Digestive System | 1 | 1995 | 29 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 368 | 0.030 |
Why?
| | Genetic Therapy | 1 | 1997 | 303 | 0.030 |
Why?
| | Blood Component Transfusion | 2 | 1994 | 99 | 0.030 |
Why?
| | Mortality | 1 | 1997 | 375 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2017 | 887 | 0.030 |
Why?
| | Vincristine | 1 | 1995 | 148 | 0.030 |
Why?
| | Hormones | 1 | 2015 | 134 | 0.030 |
Why?
| | Interleukin-3 | 1 | 1994 | 23 | 0.030 |
Why?
| | Fertility | 1 | 2016 | 173 | 0.030 |
Why?
| | Kidney | 2 | 1995 | 1491 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1500 | 0.030 |
Why?
| | Weight Gain | 1 | 2018 | 561 | 0.030 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 266 | 0.030 |
Why?
| | Pulmonary Fibrosis | 3 | 1993 | 395 | 0.030 |
Why?
| | Leukocyte Count | 5 | 1996 | 319 | 0.030 |
Why?
| | Bacterial Infections | 1 | 1996 | 246 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1070 | 0.030 |
Why?
| | Tosyl Compounds | 1 | 2014 | 17 | 0.030 |
Why?
| | Antioxidants | 1 | 2017 | 544 | 0.030 |
Why?
| | Drug Discovery | 1 | 2015 | 153 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2018 | 641 | 0.030 |
Why?
| | Child, Preschool | 6 | 2013 | 11888 | 0.020 |
Why?
| | Hand-Foot Syndrome | 1 | 2013 | 2 | 0.020 |
Why?
| | Protein Transport | 1 | 2015 | 439 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2016 | 746 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2014 | 165 | 0.020 |
Why?
| | Capecitabine | 1 | 2013 | 56 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 238 | 0.020 |
Why?
| | Necrosis | 1 | 2014 | 243 | 0.020 |
Why?
| | Erythropoietin | 1 | 1994 | 100 | 0.020 |
Why?
| | Gene Silencing | 1 | 2014 | 200 | 0.020 |
Why?
| | Binding Sites | 1 | 2016 | 1306 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2016 | 584 | 0.020 |
Why?
| | Alternative Splicing | 1 | 2015 | 249 | 0.020 |
Why?
| | Blood Cells | 1 | 1993 | 38 | 0.020 |
Why?
| | Nutritional Status | 1 | 2015 | 344 | 0.020 |
Why?
| | Recombinant Proteins | 5 | 1997 | 1361 | 0.020 |
Why?
| | CD24 Antigen | 1 | 2012 | 18 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2024 | 5875 | 0.020 |
Why?
| | Sensitivity and Specificity | 2 | 2000 | 1992 | 0.020 |
Why?
| | Anemia | 1 | 1994 | 189 | 0.020 |
Why?
| | Energy Intake | 1 | 2015 | 506 | 0.020 |
Why?
| | Diet, Reducing | 1 | 2012 | 90 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 1992 | 116 | 0.020 |
Why?
| | Models, Biological | 1 | 1999 | 1758 | 0.020 |
Why?
| | Antigens, CD34 | 3 | 1996 | 89 | 0.020 |
Why?
| | Psychotherapy, Group | 1 | 2012 | 79 | 0.020 |
Why?
| | Hyaluronan Receptors | 1 | 2012 | 105 | 0.020 |
Why?
| | Counseling | 1 | 2015 | 403 | 0.020 |
Why?
| | Emergency Medical Services | 1 | 2019 | 680 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 360 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 74 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 6050 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1700 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 326 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 2 | 1990 | 345 | 0.020 |
Why?
| | Feasibility Studies | 4 | 1998 | 1125 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2112 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2011 | 182 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 598 | 0.020 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 1990 | 36 | 0.020 |
Why?
| | Blast Crisis | 1 | 1990 | 34 | 0.020 |
Why?
| | Immunoblotting | 1 | 2010 | 294 | 0.020 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 1990 | 46 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4588 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2021 | 4565 | 0.020 |
Why?
| | Bilirubin | 2 | 2002 | 101 | 0.020 |
Why?
| | Graft Survival | 1 | 1993 | 508 | 0.020 |
Why?
| | Pemetrexed | 1 | 2010 | 40 | 0.020 |
Why?
| | Cytokines | 1 | 1998 | 2079 | 0.020 |
Why?
| | Glutamates | 1 | 2010 | 66 | 0.020 |
Why?
| | Health Status | 1 | 2015 | 822 | 0.020 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1990 | 50 | 0.020 |
Why?
| | Magnetics | 1 | 1990 | 45 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2010 | 333 | 0.020 |
Why?
| | Guanine | 1 | 2010 | 85 | 0.020 |
Why?
| | Multiple Organ Failure | 2 | 2002 | 122 | 0.020 |
Why?
| | Urologic Diseases | 1 | 1990 | 42 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2012 | 319 | 0.020 |
Why?
| | Kidney Diseases | 2 | 1991 | 427 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1270 | 0.020 |
Why?
| | Microspheres | 1 | 1990 | 142 | 0.020 |
Why?
| | Health Behavior | 1 | 2015 | 801 | 0.020 |
Why?
| | Chromosome Aberrations | 1 | 1990 | 167 | 0.020 |
Why?
| | Spinal Cord Neoplasms | 1 | 1989 | 40 | 0.020 |
Why?
| | Blood | 1 | 1990 | 107 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2017 | 2783 | 0.020 |
Why?
| | Cell Movement | 1 | 2014 | 950 | 0.020 |
Why?
| | Clone Cells | 1 | 1990 | 259 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2014 | 1236 | 0.020 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 91 | 0.020 |
Why?
| | Central Nervous System Diseases | 1 | 1990 | 73 | 0.020 |
Why?
| | Hematuria | 1 | 1989 | 11 | 0.020 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1990 | 128 | 0.020 |
Why?
| | Vinblastine | 2 | 2001 | 75 | 0.020 |
Why?
| | Rats | 1 | 2017 | 5574 | 0.020 |
Why?
| | Creatinine | 1 | 1991 | 511 | 0.020 |
Why?
| | False Negative Reactions | 1 | 1988 | 61 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 2009 | 139 | 0.020 |
Why?
| | Immunophenotyping | 2 | 2000 | 324 | 0.020 |
Why?
| | DNA Methylation | 1 | 2014 | 721 | 0.020 |
Why?
| | Leukopenia | 1 | 1988 | 33 | 0.020 |
Why?
| | Lymphoma | 1 | 1990 | 251 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 186 | 0.020 |
Why?
| | Hospitals, Veterans | 1 | 2009 | 256 | 0.020 |
Why?
| | False Positive Reactions | 1 | 1988 | 124 | 0.020 |
Why?
| | Histones | 1 | 2014 | 670 | 0.020 |
Why?
| | Drug Interactions | 1 | 1990 | 403 | 0.020 |
Why?
| | Electrophoresis | 1 | 1988 | 31 | 0.020 |
Why?
| | Antigens, Differentiation | 1 | 1988 | 75 | 0.020 |
Why?
| | Transfection | 1 | 2010 | 914 | 0.020 |
Why?
| | Phenylurea Compounds | 1 | 2009 | 122 | 0.020 |
Why?
| | Estrogen Receptor Modulators | 1 | 2008 | 14 | 0.020 |
Why?
| | Perilipin-1 | 1 | 2008 | 16 | 0.020 |
Why?
| | Niacinamide | 1 | 2009 | 103 | 0.020 |
Why?
| | Neurons | 1 | 2017 | 1663 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2017 | 2591 | 0.020 |
Why?
| | S100 Proteins | 1 | 2008 | 33 | 0.020 |
Why?
| | Staining and Labeling | 1 | 1988 | 148 | 0.020 |
Why?
| | Antigens, Surface | 1 | 1988 | 155 | 0.020 |
Why?
| | Macrophages | 2 | 1995 | 1530 | 0.020 |
Why?
| | Vimentin | 1 | 1988 | 47 | 0.020 |
Why?
| | Androstadienes | 1 | 2008 | 77 | 0.020 |
Why?
| | Community Health Services | 1 | 2009 | 229 | 0.020 |
Why?
| | Exercise Therapy | 1 | 2012 | 486 | 0.020 |
Why?
| | Nervous System Diseases | 1 | 1991 | 286 | 0.020 |
Why?
| | Central Nervous System | 1 | 1990 | 278 | 0.020 |
Why?
| | Sarcoma, Kaposi | 1 | 1988 | 82 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2455 | 0.020 |
Why?
| | Bone Marrow Purging | 2 | 1996 | 3 | 0.020 |
Why?
| | Clinical Trials, Phase II as Topic | 2 | 2000 | 74 | 0.020 |
Why?
| | Lung Diseases | 2 | 1992 | 787 | 0.020 |
Why?
| | Biomarkers | 1 | 2018 | 4329 | 0.020 |
Why?
| | Heart Diseases | 1 | 1990 | 341 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1403 | 0.020 |
Why?
| | Risk | 2 | 2000 | 917 | 0.010 |
Why?
| | Academic Medical Centers | 1 | 2009 | 560 | 0.010 |
Why?
| | Phosphoproteins | 1 | 2008 | 319 | 0.010 |
Why?
| | Stem Cell Transplantation | 1 | 2007 | 189 | 0.010 |
Why?
| | Gastrointestinal Diseases | 1 | 2008 | 220 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 1990 | 899 | 0.010 |
Why?
| | Bevacizumab | 1 | 2006 | 167 | 0.010 |
Why?
| | Quality of Health Care | 1 | 2009 | 692 | 0.010 |
Why?
| | Melanoma | 2 | 1988 | 764 | 0.010 |
Why?
| | Body Mass Index | 1 | 2012 | 2446 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 728 | 0.010 |
Why?
| | Ascites | 1 | 2002 | 47 | 0.010 |
Why?
| | Phenotype | 1 | 2010 | 3186 | 0.010 |
Why?
| | Brain | 1 | 2014 | 2981 | 0.010 |
Why?
| | Carcinoma, Lewis Lung | 1 | 2001 | 16 | 0.010 |
Why?
| | Carcinoma, Large Cell | 1 | 2001 | 17 | 0.010 |
Why?
| | Transplantation Conditioning | 1 | 2002 | 191 | 0.010 |
Why?
| | Phytohemagglutinins | 1 | 2000 | 29 | 0.010 |
Why?
| | CD4-CD8 Ratio | 1 | 2000 | 23 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2000 | 49 | 0.010 |
Why?
| | Hypersensitivity, Delayed | 1 | 2000 | 30 | 0.010 |
Why?
| | Drug Synergism | 1 | 2001 | 353 | 0.010 |
Why?
| | Skin Tests | 1 | 2000 | 94 | 0.010 |
Why?
| | Microcomputers | 1 | 2000 | 17 | 0.010 |
Why?
| | Hemorrhage | 2 | 1998 | 824 | 0.010 |
Why?
| | Louisiana | 1 | 2000 | 30 | 0.010 |
Why?
| | Philadelphia | 1 | 2000 | 55 | 0.010 |
Why?
| | Immunoglobulins | 1 | 2000 | 162 | 0.010 |
Why?
| | Graft vs Host Disease | 1 | 2002 | 280 | 0.010 |
Why?
| | Automation | 1 | 2000 | 104 | 0.010 |
Why?
| | Immunity | 1 | 2000 | 140 | 0.010 |
Why?
| | Lipopolysaccharide Receptors | 1 | 1999 | 88 | 0.010 |
Why?
| | Marriage | 1 | 1980 | 122 | 0.010 |
Why?
| | Lung | 1 | 1992 | 4119 | 0.010 |
Why?
| | Personnel Selection | 1 | 1980 | 90 | 0.010 |
Why?
| | Interleukin-4 | 1 | 1999 | 207 | 0.010 |
Why?
| | Thalassemia | 1 | 1998 | 6 | 0.010 |
Why?
| | Receptors, Purinergic P1 | 1 | 1998 | 30 | 0.010 |
Why?
| | Heart Failure | 1 | 1992 | 2323 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2000 | 403 | 0.010 |
Why?
| | Reference Values | 1 | 2000 | 787 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2000 | 413 | 0.010 |
Why?
| | Acute Disease | 1 | 2001 | 1033 | 0.010 |
Why?
| | Pilot Projects | 2 | 1994 | 1878 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2009 | 6449 | 0.010 |
Why?
| | Filgrastim | 1 | 1997 | 13 | 0.010 |
Why?
| | Adenoviruses, Human | 1 | 1996 | 26 | 0.010 |
Why?
| | Heparin | 1 | 1998 | 246 | 0.010 |
Why?
| | Killer Cells, Natural | 1 | 2000 | 481 | 0.010 |
Why?
| | Tissue Plasminogen Activator | 1 | 1998 | 244 | 0.010 |
Why?
| | Freezing | 1 | 1996 | 84 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2000 | 1136 | 0.010 |
Why?
| | Pregnancy | 1 | 2009 | 7217 | 0.010 |
Why?
| | Lymphoma, B-Cell | 1 | 1998 | 149 | 0.010 |
Why?
| | Lymphocyte Depletion | 1 | 1996 | 135 | 0.010 |
Why?
| | Genes, Reporter | 1 | 1996 | 273 | 0.010 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2001 | 627 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1995 | 99 | 0.010 |
Why?
| | Reticulocyte Count | 1 | 1994 | 7 | 0.010 |
Why?
| | Kidney Function Tests | 1 | 1995 | 154 | 0.010 |
Why?
| | Topotecan | 1 | 1994 | 17 | 0.010 |
Why?
| | Incidence | 1 | 2001 | 2910 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1859 | 0.010 |
Why?
| | Antigens, CD | 1 | 1996 | 559 | 0.010 |
Why?
| | Urinary Bladder Diseases | 1 | 1993 | 18 | 0.010 |
Why?
| | Glioblastoma | 1 | 1996 | 349 | 0.010 |
Why?
| | Heart | 1 | 1997 | 624 | 0.010 |
Why?
| | Boston | 1 | 1993 | 90 | 0.010 |
Why?
| | Registries | 1 | 2002 | 2382 | 0.010 |
Why?
| | Flow Cytometry | 1 | 1996 | 1160 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1995 | 588 | 0.010 |
Why?
| | Iron | 1 | 1994 | 359 | 0.010 |
Why?
| | Cell Line | 1 | 1996 | 2809 | 0.010 |
Why?
| | Immunologic Factors | 1 | 1993 | 244 | 0.000 |
Why?
| | Cystitis | 1 | 1990 | 24 | 0.000 |
Why?
| | Palliative Care | 1 | 1998 | 1032 | 0.000 |
Why?
| | Prostatic Neoplasms | 1 | 1996 | 972 | 0.000 |
Why?
| | Metabolic Clearance Rate | 1 | 1989 | 115 | 0.000 |
Why?
| | Introns | 1 | 1990 | 257 | 0.000 |
Why?
| | Platinum | 1 | 1989 | 48 | 0.000 |
Why?
| | Macrophage-1 Antigen | 1 | 1988 | 26 | 0.000 |
Why?
| | Brain Diseases | 1 | 1990 | 157 | 0.000 |
Why?
| | Bone Marrow Examination | 1 | 1988 | 5 | 0.000 |
Why?
| | Drug Combinations | 1 | 1990 | 399 | 0.000 |
Why?
| | Erythrocyte Count | 1 | 1988 | 20 | 0.000 |
Why?
| | Platelet Count | 1 | 1988 | 94 | 0.000 |
Why?
| | Methods | 1 | 1988 | 68 | 0.000 |
Why?
| | Pelvic Neoplasms | 1 | 1988 | 24 | 0.000 |
Why?
| | Erythroblasts | 1 | 1988 | 18 | 0.000 |
Why?
| | Infant | 1 | 2002 | 10093 | 0.000 |
Why?
| | DNA Damage | 1 | 1990 | 437 | 0.000 |
Why?
| | Acute Kidney Injury | 1 | 1995 | 861 | 0.000 |
Why?
| | In Vitro Techniques | 1 | 1988 | 1041 | 0.000 |
Why?
| | Fever | 1 | 1988 | 320 | 0.000 |
Why?
| | Pneumonia | 1 | 1992 | 633 | 0.000 |
Why?
| | Statistics as Topic | 1 | 1987 | 277 | 0.000 |
Why?
|
|
Elias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|